Axcan Nova Scotia 1 ULC Watch

EX-10.18

from S-4/A 8 pages Incentive Compensation Plan

12/34/56

EX-10.17

from S-4/A 31 pages Axcan Holdings Inc. Management Equity Incentive Plan Adopted April 15, 2008

12/34/56

EX-10.16

from S-4/A 17 pages Axcan Pharma Inc. Severance Pay Plan

12/34/56

EX-10.15

from S-4/A 6 pages October 5, 2007 Confidential Mr. Nicholas Franco 21 Rue Boulainvilliers 75016 Paris Dear Nicholas: We Are Pleased to Confirm in Writing the Terms and Conditions of Your Position as Président Directeur Général of Our French Subsidiary, Axcan Pharma SA (The “Company”), as Such Terms and Conditions Are Further Set Out in This Letter (“Letter Agreement”). Should You Agree With the Terms of This Letter Agreement, Your Appointment Would Become Effective as Soon as It Is Formally Instrumented in a Decision of the Company’s Competent Corporate Body (The “Effective Date”). a Copy of the Company’s By-Laws Is Attached as Exhibit 1 to This Letter Agreement (The “By-Laws”)

12/34/56

EX-10.21

from S-4 7 pages Penny Option Grant Agreement

12/34/56

EX-10.20

from S-4 7 pages Restricted Stock Unit Grant Agreement

12/34/56

EX-10.19

from S-4 7 pages Restricted Stock Unit Grant Agreement

12/34/56

EX-10.18

from S-4 22 pages Form of Axcan Holdings Inc. Management Stockholders’ Agreement

12/34/56

EX-10.14

from S-4 16 pages Employment Agreement

12/34/56

EX-10.13

from S-4 16 pages Employment Agreement

12/34/56

EX-10.12

from S-4 17 pages Employment Agreement

12/34/56

EX-10.11

from S-4 16 pages Amendment and Restatement of Employment Agreement

12/34/56

EX-10.10

from S-4 20 pages Guaranty Dated as of February 25, 2008 Among Axcan Midco Inc., Axcan Intermediate Holdings Inc., Axcan US Partnership 1 LP, Certain Other Subsidiaries of Axcan Intermediate Holdings Inc. Identified Herein and Bank of America, N.A., as Administrative Agent

12/34/56

EX-10.8

from S-4 35 pages [ ** ] = Portions of This Agreement Have Been Omitted From This Exhibit Pursuant to a Request for Confidential Treatment. an Unredacted Version of This Agreement Has Been Filed Separately With the Securities and Exchange Commission. Supply Agreement Between Paddock Laboratories, Inc. and Axcan Pharma Inc. Dated: May 7, 2004

12/34/56

EX-10.7

from S-4 37 pages [ ** ] = Portions of This Agreement Have Been Omitted From This Exhibit Pursuant to a Request for Confidential Treatment. an Unredacted Version of This Agreement Has Been Filed Separately With the Securities and Exchange Commission. Manufacturing Services Agreement Between Patheon Inc. and Axcan Pharma Inc. October 1, 2003

12/34/56

EX-10.6

from S-4 38 pages [ ** ] = Portions of This Agreement Have Been Omitted From This Exhibit Pursuant to a Request for Confidential Treatment. an Unredacted Version of This Agreement Has Been Filed Separately With the Securities and Exchange Commission. Finished Product Supply Agreement

12/34/56

EX-10.5

from S-4 53 pages [ ** ] = Portions of This Agreement Have Been Omitted From This Exhibit Pursuant to a Request for Confidential Treatment. an Unredacted Version of This Agreement Has Been Filed Separately With the Securities and Exchange Commission. Exclusive Development/License/Supply Agreement Between Eurand International S.P.A., via Martin Luther King, 13 20060 Pessano Con Bornago (Milan) (Italy) and Axcan Scandipharm, Inc. 22, Inverness Center Parkway Birmingham, Al 35242 (U.S.A.) for Eurand Minitabs® Pancrelipase With Hp55 Coating

12/34/56

EX-10.4

from S-4 18 pages W I T N E S E T H

12/34/56

EX-10.3

from S-4 63 pages Taylor & Mathis of Alabama, Inc. Brokers-Developers Inverness Center Birmingham, Alabama

12/34/56

EX-10.2

from S-4 3 pages Joinder to Management Services Agreement

12/34/56